Why the study?
Does intravenous and oral flecainide terminate and prevent symptomatic and refractory tachyarrhythmias in children?
Does intravenous and oral flecainide terminate and prevent symptomatic and refractory tachyarrhythmias in children?
Intravenous and oral flecainide are safe and effective for terminating and preventing symptomatic and refractory tachyarrhythmias in infants and children.
Answers are grounded in this paper and cite their sources.
May support flecainide in refractory pediatric cases; leaves open confirmation of safety and efficacy in randomized trials.
Nine children, aged 2.5 months to 16 years, presenting with tachyarrhythmias were treated with intravenous (i.v.) flecainide, a type 1C antiarrhythmic drug. There were four boys and five girls; seven were supraventricular and two ventricular tachycardias and three had structural cardiac abnormalities. The i.v. dose required to terminate the arrhythmias ranged from 1.0 to 2.4 mg/kg (mean 1.55 mg/kg) although a mean of 1.94 mg/kg per dose was required to maintain sustained sinus rhythm after a single i.v. dose. Eight of the patients--six supraventricular and two ventricular tachyarrhythmias, required maintenance oral flecainide. Oral dosages of 6.7-9.5 mg/kg per day (mean of 7.97 mg/kg per day in three divided doses) were required to effectively prevent the tachyarrhythmias. Intravenous and oral flecainide are safe and effective in terminating supraventricular and ventricular tachyarrhythmias. No evidence of proarrhythmia was found in the patients during follow up of between 5 and 9 months. The present limitation of performing radiofrequency ablation on infants and small children justifies the important place of medical therapy for re-entrant supraventricular tachyarrhythmias.
No takes yet. Share an insight, caveat, or question.
Ismail et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: